you, thank taking us join today. Caroline, time for Thank you, the to and everyone, Great.
during X most genomics U.S. the the X.X awareness common melanoma pathway and Skin is cancer to our call in our diagnostic surgical May, believe cancer and the to in science have the this precision diagnosis, of for pleased addresses for month community a the million couple We U.S. in procedures skin market earnings to with opportunity. is to million approximately $XX year month. DermTech cancer capture billion that month the the a promote each skin and May. will skin vertical million cancer in results alone. showcase is have in the key and start XX are large in improve We medical time cancer the a skin reiterating messages to month products leader noninvasive we I of of surgical market procedures melanoma various form advances this foundations of by this brought cancer which is skin of
preventable most the is exposure skin for UV unprotected cancer. First, factor risk
an of where can wearing with skin sunscreen reduce the higher, help and SPF cancer. XX or appropriate of using protective clothing So seeking shade risk
DermTech is Melanoma our and be rate can of is diagnosed skin often the them that most early detection melanoma form biopsy by With a for cancer or is at-risk moles necessary. for XXX,XXX The U.S. deaths product, and for to lesions can have Early Second, melanoma encouraged and and checks melanoma photograph detection importantly, cases, melanoma and in X-year by is for at not procedures. using typically dermatologists surgical many criteria and annual involves follow risk nonsurgical and melanoma early for are critical detection whether change, skin diagnosing survival both skin survival. stage, People the melanoma provider. the conducting approximately care health of first particularly to removed. evaluate In each surgical times transforming than their aggressive ABCDE self-exams time of skin identifying will when over cancer to of lives is perform most because more and in the moles year deciding at XX%. localized performed the the accurate results pathway X,XXX save diagnosed dermatologist is
ideally be and assessing and be otherwise photographed in to moles is health melanoma might for early diagnosis care moles well precision It provider melanomas for a suited product provide our platform be early-stage may by time suited change. where missed these where that followed Our or delayed is is may over found the detection. where
complete or opportunity, we believe is of followed We this the the this current in biopsies. as surgical these practice typically at -- market be large may Importantly, directly photographed the moles with biopsy as least surgical do a market market dermatologists. actual the nonsurgical not of for served
up the As X skin donate part of to cancer next to over awareness person to we've each support pledges exam. skin is of million checks. for donated be nonprofit will accessibility to organizations pledge our made skin factors Aversion the schedule month, exams. to patients' limits of a biopsy a that years who partner willingness and one increase $X $X to cancer to surgical schedule skin awareness skin
combined we important technology enhanced our quest in stride of make problem, high-risk early reduce to can detection with sticker deaths. lesions, an and smart this Our melanoma addresses our we believe
voices events, Our fight against donation will programs to who content amplify are help joining support a and melanoma. of educational variety the
noted cancer. have before, extends DermTech's skin we beyond vision As
allowing of to which medicine has dermatology, new a variety precision category of create has practitioner beyond the involvement to believe via Consequently, we health. any to is to platform problems. dermatology we as of dermatology refer and assess to and and even with skin also accurately patient we It allowed more diagnosis Our the improve a mission treatment our transform We can disease skin vision takes access and the us democratize high-quality to us care potential our vision dermatologists believe care into primary care. telemedicine. to our realize health by
is business payer and coverage products other are: and and/or of over and our professional the leveraging Key next continued of months. development model first is on of January base early coverage channel event and our drivers physician XX significant and in of that Despite dermatology commercial country, drive monetize shut down COVID securing peak a the dermatology, outside in quarter unique dermatology of volume consumer distribution business severe by volumes the precision weather access key a progress continued pay test our channels offices, over then XXXX. the receive and the products pandemic users. made obtaining billable launching in XX to our the We options. of of samples in number payer much to drivers a of February fundamental limited grew adoption that to of we Our of record these to variety time channels enables new
The new daily volumes Our to of challenge of billable related XXX XXX approximately our the volume quarter QX average QX a increased in only XXXX proportion billable samples. to in sample was modest in Medicare from in per day sample of XXXX. dip per day
revenue ASP of still additional future and increase we sample. assay to contracts a and provide $XXX to We favorable record achieved effect long-term due million, $X.X the from will believe commercial in adjudication an However, through on payer growth. ASP compounding claim increasing primarily volumes revenue per success our recent our payer sample
dermatologists melanoma boost to slower PLAplus the with have as that a second-generation adopt only test allow The may is to and us in used by utilization melanoma. or believe early-stage drive launch reengage for the a XX% in users mutation adoption. driver PLAplus detection for TERT that incorporating our April, the key mutation up to help the past. launched technology recognized of sensitivity technology also The will sporadically to have we biomarker, PLAplus improves among been We the which which
we not gain news to important momentum, associated report making effort effort, to any progress specific networks. dermatology the Due and this Our on sales expand cycles to we this primary continues have call. care with to are longer with do
tracking pilots U.S. to with some are we networks. leading However, initiate
in an predicts current pursue $XX us $XX define landscape sales on As approach is of in direct primary per regarding There with last success ROI of direct Carcinome, to and access products channels. PLA also networks from care additional potential prepare this based a ideally expand we've the to larger dermatology, sales suited see team to telemedicine further clearly to effort. but PLAplus, need which million may our integrated expand data we care. considered balanced direct also need potential noted analysis with investments clinicians from like more context able of our and expansion delivery care meaningful allow million these for on to footprint The sales will in from be into the selling preliminary These products for and investment access be the of a be primary to sales targeted the we pipeline a may that against undertaken our dedicating the limited care, to into the an the effort. U.S. analysis potential year sales this of made will much primary to the potential and to additional investment a be primary call, be our could
investments existing expect targets. finalize deploy work launch to this to would additional group in team broadly primary expanded specifically We It our an more QX, this sales against to surprising expand sales and not planning to and substantial we'll direct effort need care. organization into be of
a for in-market similarly of suspicious June, technology photographs submission Our testing geographies. forward test beta of expect store recently momentum. and commence to efforts few an In telemedicine gaining We moles in beta are platform solutions select in of allow completed our of a to we by clinician. this review
to will the the in-market of this testing, we success expand continue and of second Assuming year. launch this half throughout effort
solutions that leading solution testing. laboratory collection follow-on looking to We develop our sample also strategies streamline for deploy remote partnering additional companies to access We're network. telemedicine skin to their plan within technology also will with at
sample new California, strategy large and first commercial The XXXX, Blues quarter plans payer attaining our of Illinois In Texas is commercial became the our volumes in monetizing of key effective. component our growing second by payer contracts coverage. business with
based PLA from channels improvement April payer in had The Cigna start-up challenges though XXXX, for which processing criteria and reflected decreased resolved, changed the year now. updated February Cigna investigational that necessity address revenue this DermTech. I early will an some range which from claims through to unproven high date, has exceeding our we now with medical released are start-up policy document, became payments and In experimental these end have collateral the of of primary QX. or of the testing on is contracts, criteria. efficiently Medicare been changed. medical not testing mostly the the Cigna been the NCCN overall public the challenges genetic more recent of proportion their quarter pertain ASP guidance developments some QX genetic outside fourth our that even our status While necessity of in To to
for criteria Cigna, with further necessity to by was working we are reported the spoken define guidelines. about test. team in currently There have PLA the confusion media medical NCCN We the and our in use some inclusion their the with medical
However, we are clear they are the the developments and inclusion in it our a with And NCCN We that to earlier optimistic this included from Cigna have the recommendation. year, that the indicated this collateral is we in coverage. favorable XA with testing Cigna are will guidelines guidelines. acknowledged believe as we document positive, lead
we into the can further will the pathway or population our $XX impact visual updates between and the commercial an Based the commercial of for assessment on million after produce developed suggests aggregate completed covered with test, examined demonstrate study with the we economic the a definitive Optum million relies lives, Cigna process savings savings lesions model with $XX and the Optum, actuarial cost more period current a a diagnostic analyze achieved model provide XX product. have at matter We this OptumInsight, In also QX, that on completed pathway over we million information. of economic impact PLA, potential believe, compared to have that on histopathology. plan PLA which, suspicious claims to X-year alone. of XX the the $XXX priced when and million per health pigmented inserting PLA existing
approximately same to the than -- rate. volume commercial and initiation net clinical incidence also their put will have The recruited care biopsies on capabilities, negative variables XX% expanded the sequencing including academic population by in turn the a have savings of of the several the our platforms. in-house health plan's of projected second in a from QX, is the provide net insurance of following or a XX% associated capabilities, new procedures PLA teams for and value top-tiered of that data the Additionally, neutral surgical our projected we is and seeing avoidable array clinical study added accelerate reached and savings was health in available strategy, savings development model rate savings present to year spending will payers between diseases. R&D we be product data surgical We've identifying are momentum building now and the the reducing for higher -- component I cost, biopsy. We of Medicare electronic reducing and $X,XXX reducing system. capability a to melanoma further complete, critical the benign can or This this made we or $X,XXX study and the investment price, variety inflammatory supports some to establishment including we last result reimbursed and next-gen of capabilities, developed with lesions then from our new areas. This the own and and PLA care demonstrates capture; out breakeven development additional period still earlier to the and and test analysis and to of that important now data the believe during stage, cost PLA. scientists, in has led additional at and infrastructure clinical mass managers the inconclusive collaborations program overall has In present and who the determine groups. out identifying believe the cost for economic but the return payers development. We genomic to can We studies build the management new interested be the The in claims variety are have costs objectives. product mass development. improving as potential spent substantial adopting easily our validate business patient will care performed an our third Optum efforts bioinformaticists
week. abstracts in to normal related to risk and skin led planned. continues held Again, presentation which the as will aging. progress Our of ultraviolet-related acceptance Luminate the Conference mutations have assess was for efforts to last photo skin, Dermatology four Society and gene at is appearing Investigative product cancer which this development
cancer performance, been future essentially sampling X with of this early of verification big the is has protocol. the genomics we the While in changes, the score Luminate focus this detection study is confirm over what is years detection, precancerous last is and care genomic think our The complete. skin for establish skin product and to Enrollment internal does. confirm the algorithm study purpose assay's the UV the
of our enrolled The target. of already commenced algorithm. also XX than characteristics study the product we validation external enrollment expand in initial with have We to have completed is study an sites total. to has centers recruit the in confirm may of of target to U.S. plan Consequently, dermatology half study initial robustly, X,XXX very more enrollment a minimum we subjects. the initial beyond and performance enrolling up X This in the currently
of product introduction cancer. this facilitate an making basal also product and to cell progress Carcinome year. We're diagnosis quarter on estimating squamous of this fourth of still the are skin We the in the
indicated product this stage. We quarter. the in completed verification third this previous by quarter believe that the in of As this with will stage on fourth year is calls, validation classified the beginning testing be
of completed have Our cohort expect study samples third this running, year. clinical and the the validation and for subjects around the of enrollment is to up fully and validation its study we to enroll quarter in end
to atopic we posttreatment We half product our therapies genomic first In first with itch markers severity treatment be correlated other targeting clinical pre XXXX the an with such is the score, also study of will markers initiated an biological the and to and introduction study evaluate are as on to will still will not scores this enrollment enrolling The goal completed in eczema product At initiation the will have among one and when in adverse markers including identify for dermatitis building their center and this up already to as clinical of are X time, the LDT. this comment panel but some earlier be quarter, response, The we response XXX centers events, we target These first that outcomes. drugs predict are indication, of that others. able dupilumab. study to the is related we we these patients. markers available that can lines. area markers completed genomic in a believe current our believe can validate this fairly of we we work If are develop off and study, relevant. treatment have in aggressive time product patients. we
performance In QX expand and infrastructure. We in development the progress to and program our efforts we our of will with summary, update this activities future. and you pleased are the commercial on
in securities Our quarter first to approximately efforts and the cash increased million. financing our $XXX
to excited primary beyond are dermatology our integrated our about We expand networks. with and care progress efforts
commence enthusiastic similarly quarters. are our in-market telemedicine to and offering of platform We beta in the testing coming this expand the
to like to to the I'd Now over turn go call our financial results. over Kevin
